You are on Trendlyne United States. Click here to go to India website or make United States as your default
person reading

About Collegium Pharmaceutical Inc - Company Information, Overview, History and Profile

What does Collegium Pharmaceutical Inc do?

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Collegium Pharmaceutical Inc Management structure

All Gross Remunerations are in USD
Ms. Shirley R. Kuhlmann
Executive Vice President, General Counsel, Secretary and Chief Administrative Officer
-
2025
Gross Remuneration
Year
Mr. David Dieter
Executive Vice President and General Counsel
-
2025
Gross Remuneration
Year

Collegium Pharmaceutical Inc Board of directors

All Gross Remunerations are in USD
Ms. Nancy S. Lurker
Independent Director
-
2025
Gross Remuneration
Year
Mr. Gino Santini
Lead Independent Director
-
2025
Gross Remuneration
Year
Dr. Carlos V. Paya,M.D.,PhD
Director
-
2025
Gross Remuneration
Year
Mr. Michael T. Heffernan, R.Ph.
Chairman of the Board
-
2025
Gross Remuneration
Year
Ms. Gwen A. Melincoff
Independent Director
-
2025
Gross Remuneration
Year